Abstract
Aim
To clarify the 2-year efficacy of ranibizumab for patients with polypoidal choroidal vasculopathy (PCV) with recurrent or residual exudation from branching vascular networks after previous photodynamic therapy (PDT).
Methods
We retrospectively reviewed 26 eyes of 26 Japanese patients (22 men, 4 women) in this pilot study. All eyes had PCV with complete regression of polypoidal lesions resulting from PDT detected by indocyanine green angiography (ICGA), but recurrent or residual leakage from branching vascular networks on fluorescein angiography and evidence of persistent fluid on optical coherence tomography (OCT). Three consecutive intravitreal injections of ranibizumab (0.5 mg/0.05 ml) were administered to all eyes.
Results
The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly from 0.55 at baseline to 0.35 at 12 months (P<0.0001) and 0.43 at 24 months (P=0.0012). The mean increases in the BCVA 12 and 24 months after baseline were 1.95 and 1.23 lines, respectively. The mean central retinal thickness significantly decreased from 295 μm at baseline to 189 μm at 12 months (P<0.0038) and 163 μm at 24 months (P<0.001). The mean numbers of intravitreal ranibizumab (IVR) injections at months 12 and 24, including the initial treatments, were 5.8 and 8.8, respectively. Five (19.2%) eyes had recurrent polypoidal lesions on ICGA at a mean of 15.7 months after baseline. At month 24, OCT showed no exudation in 17 (65.4%) of the 26 eyes. No adverse events developed.
Conclusions
IVR injections maintained or improved the VA and retinal thickness at 24 months in eyes with PCV with recurrent or residual exudation from branching vascular networks after previous PDT.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B . Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10: 1–8.
Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA . Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995; 15: 100–110.
Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA . The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115: 478–485.
Maruko I, Iida T, Saito M, Nagayama D, Saito K . Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144: 15–22.
Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ . Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 2000; 238: 752–759.
Scassellati-Sforzolini B, Mariotti C, Bryan R, Yannuzzi LA, Giuliani M, Giovannini A . Polypoidal choroidal vasculopathy in Italy. Retina 2001; 21: 121–125.
Ladas ID, Rouvas AA, Moschos MM, Synodinos EE, Karagiannis DA, Koutsandrea CN . Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in a Greek population. Eye 2004; 18: 455–459.
Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW . Incidence and clinical 182 patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol 2008; 52: 57–62.
Tano Y, Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology 2008; 115: 585–585.
Saito M, Iida T, Nagayama D . Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92: 1642–1647.
Akaza E, Mori R, Yuzawa M . Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008; 28: 717–722.
Saito M, Nagayama D, Iida T . Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy: long-term results. Nippon Ganka Gakkai Zasshi 2009; 113: 792–799 (in Japanese).
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et alMARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et alANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2–13.
Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92: 70–73.
Kokame GT, Yeung L, Lai JC . Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: an Interim 6-month report. Br J Ophthalmol 2010; 94: 297–301.
Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in japanese patients. Am J Ophthalmol 2012; 154: 117–124.
Saito M, Iida T, Kano M . Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina 2011; 31: 1589–1597.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol 1999; 117: 1329–1345.
Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43–58.
Saito M, Iida T, Kano M . Combined Intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2012; 32: 1272–1279.
Saito M, Iida T, Kano M . Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012; 32: 1250–1259.
Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008; 146: 513–519.
Akaza E, Yuzawa M, Mori R . Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011; 55: 39–44.
Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu JR et al. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. Retina 2010; 30: 1197–1205.
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST Study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453–1464.
Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T . Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151: 594–603.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflicts of interest.
Disclaimer
The authors have no proprietary interest in any aspect of this study and received no government funding.
Rights and permissions
About this article
Cite this article
Saito, M., Iida, T., Kano, M. et al. Two-year results of intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Eye 27, 931–939 (2013). https://doi.org/10.1038/eye.2013.114
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2013.114
Keywords
This article is cited by
-
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Scientific Reports (2019)
-
Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy
Japanese Journal of Ophthalmology (2018)
-
High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population
Eye (2015)
